Michel Attal.

Its use is associated with improved myelotoxicity and increased risks of thromboembolism and second primary cancers. Together with the findings reported by McCarthy et al.,19 our data support the use of lenalidomide maintenance therapy after high-dosage chemotherapy and autologous hematopoietic stem-cell transplantation in patients with myeloma, but the impressive benefits should be weighed against the elevated risks.. Michel Attal, M.D., Valerie Lauwers-Cances, M.D., Gerald Marit, M.D., Denis Caillot, M.D., Philippe Moreau, M.D., Thierry Facon, M.D., Anne Marie Stoppa, M.D., Cyrille Hulin, M.D., Lofti Benboubker, M.D., Laurent Garderet, M.D., Olivier Decaux, M.D., Serge Leyvraz, M.D., Marie-Christiane Vekemans, M.D., Laurent Voillat, M.D., Mauricette Michallet, M.D., Brigitte Pegourie, M.D., Charles Dumontet, M.D., Murielle Roussel, M.D., Xavier Leleu, M.D., Claire Mathiot, M.D., Catherine Payen, M.D.D., and Jean-Luc Harousseau, M.D.Main outcome measure: PRM rating, graded on an 11-stage scale, and total period. Results: Individuals randomized to the iPhone program group have scored higher on the observed performance of the PRM compared to the placebo group with a mean difference of 4.98 points. Participants randomized to the placebo group regularly performed the maneuver quicker than those that had an operating iPhone application. The common placebo participant performed the maneuver in only 79.9 seconds while participants in the test group averaged 245.8 secs. In summary, preliminary testing demonstrated that individuals using the DizzyFix iPhone program conducted the PRM more accurately and slowly compared to the participants using a placebo.